Immuron Limited reported sales results for the first quarter of 2024. For the period, the company Sales of Travelan® increased to AUD 1,339,160 in Q1, FY24, compared to AUD 25,565 in Q1, FY23. Sales increased by $940,991 (236%) on the pre-pandemic peak period (Q1, FY20).

This increase partially reflects 3 months (May, June, July) of backorders accrued while awaiting GMP Clearance from the TGA. Immuron anticipates continued demand for replenishment of Travelan® as retail pharmacies sell to consumers. Australian Bureau of Statistics: short term resident returns in July 2023 were 48% higher than July 2022 and approaching pre-pandemic levels (89% of July 2019)1. Cumulative short term resident returns in the 12 months to July 2023 were 77% of those in the pre-pandemic period 12 months to July 2019.

Sales of Travelan® increased to AUD 211,080 in Q1, FY24, compared to AUD 16,614 in Q1, FY23. Sales were lower by $20,499 (-9%) on the pre-pandemic peak period (Q1, FY20). International Trade Administration Total U.S. citizen international visitor departures from the United States in June 2023 increased 20.2% compared to June 2022 and were 99.4% of total departures in June 2019.

2 Immuron?s target departure markets 3, June 2023 quarter departures were only 3% lower than the pre-pandemic period June 2019.